Back to today’s briefing

Story perspectives

Algiax's AP-325 Shows Promise in Chronic Pain Relief

2/5/2025

32 6

Summary

Algiax Unveils Painkiller

Germany's Algiax Pharmaceuticals has unveiled promising Phase IIa trial results for its non-opioid painkiller, AP-325, aimed at alleviating chronic neuropathic pain. Remarkably, over 25% of participants reported a 50% reduction in pain within just two weeks, all while maintaining a strong safety profile. This breakthrough comes on the heels of the FDA's approval of Vertex's Journavx, another innovative non-opioid treatment.

Summary

FDA Approves Journavx

The FDA has made a groundbreaking decision by approving Journavx (suzetrigine), the first non-opioid pain reliever in two decades. This revolutionary drug works by targeting sodium channels in the peripheral nervous system, providing effective pain relief without the threat of addiction. At $15.50 per pill, it shines as a beacon of hope in the fight against the opioid crisis, with exciting possibilities for treating neuropathic pain.

1 of 2

Algiax Unveils Painkiller

Germany's Algiax Pharmaceuticals has unveiled promising Phase IIa trial results for its non-opioid painkiller, AP-325, aimed at alleviating chronic neuropathic pain. Remarkably, over 25% of participants reported a 50% reduction in pain within just two weeks, all while maintaining a strong safety profile. This breakthrough comes on the heels of the FDA's approval of Vertex's Journavx, another innovative non-opioid treatment.

1 / 2